Table 1.
Case no. | 18q21.1* | SMAD4† | SMD2† | DCC† |
---|---|---|---|---|
256 | − | + | + | + |
405 | − | + | + | + |
784 | − | + | + | + |
1154 | − | + | + | + |
428 | − | + | + | − |
1121 | − | + | + | − |
859 | − | + | − | − |
780 | − | + | − | − |
1217 | − | + | − | − |
761 | − | + | − | + |
981 | − | + | − | + |
787 | − | + | − | + |
810 | − | + | − | + |
1182 | − | + | − | + |
983 | − | − | + | + |
412 | − | − | + | + |
223 | − | − | + | − |
723 | − | − | + | − |
1117 | − | − | + | − |
1183 | − | − | + | − |
1164 | − | − | + | − |
755 | − | − | − | + |
1078 | − | − | − | + |
750 | − | − | − | − |
1151 | − | 0 | 0 | 0 |
277 | + | + | + | + |
402 | + | + | + | + |
1027 | + | + | + | + |
823 | + | + | + | + |
1130 | + | + | + | + |
852 | + | + | + | + |
250 | + | + | + | + |
261 | + | + | + | + |
793 | + | + | + | + |
796 | + | + | + | + |
818 | + | + | + | + |
821 | + | + | + | + |
849 | + | + | + | + |
984 | + | + | + | + |
960 | + | + | + | + |
989 | + | + | + | + |
994 | + | + | + | + |
1053 | + | + | + | + |
1129 | + | + | + | + |
1180 | + | + | + | + |
1192 | + | + | + | + |
1106 | + | + | + | − |
779 | + | + | + | − |
846 | + | + | − | + |
201 | + | + | − | + |
828 | + | + | − | + |
1097 | + | + | − | + |
1184 | + | + | − | − |
1185 | + | − | + | + |
1195 | + | − | + | + |
795 | + | − | + | − |
769 | + | − | + | − |
995 | + | − | + | − |
1136 | + | − | + | − |
1124 | + | − | − | + |
*−, LOH at 18q21.1; +, no LOH at 18q21.1.
†+, positive immunoreactivity; −, negative immunoreactivity; 0, not interpretable.